NEW YORK (TheStreet) -- Gilead Sciences (GILD) - Get Report shares are up by 3.29% to $116.79 in after-hours trading on Tuesday, following the release of the biopharmaceutical company's 2015 second quarter earnings results.
The company reported second quarter net income of $4.49 billion, or $3.15 per diluted share on revenue of $8.24 billion.
Gilead Sciences' results topped analysts' expectations for earnings of $2.71 per share on revenue of $7.6 billion for the quarter.
Separately, the HIV vaccine and hepatitis C drug manufacturer announced a quarterly dividend of 43 cents to be paid on September 29 to shareholders of record as of September 16.
The company also upped its full year product sales expectations to between $29 billion and $30 billion, above the $28 billion to $29 billion the company had previously forecast.
Separately, TheStreet Ratings team rates GILEAD SCIENCES INC as a Buy with a ratings score of A. TheStreet Ratings Team has this to say about their recommendation:
"We rate GILEAD SCIENCES INC (GILD) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and notable return on equity. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook."